Mission Statement, Vision, & Core Values (2026) of UCB SA.

At the heart of UCB SA lies a clear promise: to improve lives of people with severe diseases through patient-centered innovation-backed by a global team of 9,000 employees spanning nearly 40 countries and a focused pipeline in neurology and immunology that channels major resources into science and collaboration; in 2024 UCB invested €1.781 billion in R&D-representing 29% of revenue-while pursuing a strategic ambition to reach €6 billion in revenue by 2025, all underpinned by core values of integrity, collaboration, innovation, sustainability, and a commitment to diversity, health and wellbeing that drives partnerships with patients, caregivers and healthcare professionals to translate breakthroughs into meaningful therapies.

UCB SA (UCB.BR) - Intro

• Workforce: >9,000 employees operating in nearly 40 countries
• Therapeutic focus: Neurology (epilepsy, Parkinson's, Alzheimer's) and Immunology (rheumatology, dermatology)
• Patient engagement: Close collaboration with patients, caregivers, HCPs, and advocacy groups to inform research, clinical trial design, and access programs

• Mission: Improve the lives of people living with severe diseases by delivering meaningful therapies that address high unmet need.
• Patient partnership: Patients and caregivers shape R&D priorities, endpoint selection, and real-world evidence collection.
• Access & affordability: Programs to broaden access globally, including tiered pricing, local partnerships, and patient support services.

• Vision: Become a leading global biotechnology company, defined by scientific excellence and transformational impact for patients.
• R&D-led growth: Significant, recurring investment in discovery, translational science, and clinical development to sustain innovation.
• Precision medicine: Leverage biomarkers, digital tools, and real-world data to personalize treatments in neurology and immunology.

• Trust & integrity: Ethical conduct across clinical, commercial, and corporate activities.
• Care: Prioritizing patient welfare and safety in decisions and product stewardship.
• Transparency & accountability: Open reporting, stakeholder dialogue, and measurable governance metrics.

• Environmental stewardship: Initiatives to reduce greenhouse gas emissions, optimize energy use, and minimize waste across manufacturing sites.
• Social impact: Community health programs, patient education, and equitable access efforts in emerging markets.
• Governance: Strong compliance programs, diversity and inclusion targets, and ethical supply-chain oversight.

• Revenue trends: Stable multi-billion euro revenue demonstrating commercial traction of core assets.
• R&D intensity: High R&D spend as a percentage of revenue to sustain pipeline progression and long-term value creation.
• Workforce and footprint: Continued global expansion with talent investments in scientific hubs and digital capabilities.

UCB SA (UCB.BR) - Overview

• Targeted therapeutic focus: neurology (epilepsy, rare epilepsies) and immunology (autoimmune and inflammatory conditions).
• Patient-centric development: co-creation with patients, caregivers and healthcare professionals to align endpoints and access strategies.
• Scientific commitment: sustained high R&D intensity to drive novel mechanisms and lifecycle innovation.

• Science-led innovation - prioritizing rigorous translational research and late-stage development to deliver meaningful clinical benefit.
• Patient relevance - designing programs and access pathways around real-world patient needs and outcomes.
• Collaboration and partnerships - working with academia, biotech, payers and patient organizations to accelerate solutions and address access barriers.
• Integrity and sustainability - ethical conduct, responsible pricing, and reinvestment in long-term R&D capacity.

• Neurology: portfolio targeting epilepsy and rare epilepsy syndromes with therapies addressing seizure control and quality of life.
• Immunology: biologics and targeted therapies for autoimmune and inflammatory diseases, advancing therapies from proof-of-concept to real-world use.

UCB SA (UCB.BR) Mission Statement

• Focus areas: neurology and immunology as core therapeutic pillars, with targeted expansion into related severe-disease populations.
• Strategic commercial ambition: lead in five defined patient populations while growing top-line performance to at least €6 billion by 2025.
• Sustainability and governance: integrate ESG performance into business metrics to secure long‑term value for patients, employees and shareholders.
• Global reach: expand presence in emerging markets and form strategic partnerships to increase access and scale.

• Deliver innovative, patient-focused medicines and care models that improve outcomes and quality of life.
• Allocate sustained R&D investment to maintain a robust pipeline across priority indications.
• Embed ESG objectives across operations - environmental footprint, social access, and corporate governance - to enhance external ratings and stakeholder trust.

• Pipeline prioritization to accelerate late‑stage assets addressing high unmet need in neurology and immunology.
• Commercial scale-up tied to revenue and patient-reach milestones, with targeted launches and lifecycle management in core markets.
• ESG-linked initiatives (responsible sourcing, emissions reduction targets, equitable access programs) to improve external ratings and stakeholder value.

UCB SA (UCB.BR) - Vision Statement

• Patient impact: prioritize high-unmet-need indications and measurable improvements in quality-adjusted life years (QALYs) for targeted populations.
• Science-driven growth: translate novel biology into late-stage assets and commercial medicines to expand global access.
• Responsible leadership: align commercial expansion with environmental targets, diversity goals, and robust governance.

• Integrity - All decisions and behaviors adhere to ethical and compliance standards, supporting transparent reporting and stakeholder trust. Internal compliance metrics and third-party audits are part of governance to ensure consistent adherence.
• Collaboration - Strategic partnerships with academia, biotech, and patient organizations accelerate translational research and access. UCB's external collaborations account for a significant portion of late-stage pipeline sourcing, enabling faster go-to-market timelines.
• Innovation - R&D investment focuses on first-in-class and best-in-class candidates, with a disciplined portfolio approach targeting unmet medical needs in neurology and immunology.
• Sustainability - Active measures to cut greenhouse gas emissions and waste, reduce water intensity, and promote circularity in manufacturing and packaging.
• Diversity, Equity & Inclusion (DEI) - Policies and programs to build diverse talent pipelines, equitable career progression, and inclusive leadership behaviors across global sites.
• Health, Safety & Wellbeing - Workplace safety programs, mental health support, and wellbeing initiatives to retain talent and maintain high operational standards.

• Integrity: compliance-driven commercial policies, third-party transparency disclosures, and adverse-event reporting systems integrated across markets.
• Collaboration: co-development agreements and licensing deals that contributed multiple late-stage assets and reduced time-to-clinic for novel modalities.
• Innovation: allocation of roughly one-quarter of revenues into R&D to sustain a robust early- and late-stage pipeline focused on disease-modifying therapies.
• Sustainability: initiatives in manufacturing energy efficiency, renewable sourcing, and sustainable packaging that together lowered Scope 1-2 emissions materially.
• DEI: global recruitment and leadership-development targets with measurable representation goals and retention metrics.
• Health & Wellbeing: global EHS programs, employee assistance services, and site-level health metrics driving lower incident rates and improved engagement scores.

• Investment in R&D and partnerships supports a balanced growth profile-commercial revenue plus pipeline-driven valuation upside.
• Sustainability and DEI performance increasingly factor into investor due diligence and cost of capital considerations.
• Robust governance and integrity frameworks reduce regulatory and reputational risk, preserving market access and long-term shareholder value.